Anti-Aging Genes

Question: Can you define the aging process for humans?

Leonard Guarente: Aging process -- you can describe it statistically in terms of mortality curves, and what that means is that the probability of dying increases with your age. And the reason is that there's a degenerative process that's occurring in cells and tissues that makes you increasingly less robust as you get older, and opens up the doors to diseases of aging, the major diseases -- diabetes, Alzheimer's disease, cancer, cardiovascular disease, osteoporosis -- and eventually will kill you. So it's a very pervasive process that has many, many things going wrong all at the same time.

Question: What have been the key breakthroughs in the last decade in understanding aging?

Leonard Guarente: Well, you're talking to somebody who is not unbiased in this area. And you know, I think the sirtuins have really been, to my mind, the completely unexpected new thing to come along. Now, this came from the studies in yeast that I described a few minutes ago, where we were looking for anti-aging genes. And after about nine years of doing this , the first nine years -- we started working in this area about 19 years ago -- the first nine years were spent in yeast, trying to find the right gene. And we came upon a gene called SIR2. And the SIR2 gene was an anti-aging gene. And what I mean by that is, when you made it more active, the cells lived longer; they divided more times. When you made it less active, they lived less long. So this looked like a really interesting gene, and it was the only gene that we came across that did this. And so we thought it was interesting.

Then we carried out a similar kind of study in a different organism that people study in the lab, the roundworm, C. elegans, and again we're looking: are there any genes in the genome of C. elegans that are anti-aging genes? And we got the same gene; we got a gene that had the same sequence, similar sequence, as the yeast SIR2. So that's an amazing finding, because what it means is, if the SIR2 gene is counteracting aging in yeast and in worms that it's doing that universally. And that would include mammals, and it would include us. So it really right away speaks to a universality of this process. So I think that's one thing that's highly significant about this, is that the gene is conserved, and we think its effect on the aging process is conserved.

Now, the piece of this that makes it, I think, particularly exciting is, you say, well, okay, there's this gene that makes you live longer if it's more active. Why should that be? What does this gene actually do? Okay? And what we know is, genes, of course, are the blueprint to specify proteins, and the SIR2 genes encode particular proteins. The proteins are called sirtuins, okay? And we were really, really eager to find out what the sirtuins actually did in cells. And just almost exactly 10 years ago, a little bit more than 10 years ago, we discovered it. And they have an enzymatic activity in cells that enables them to modify other proteins in cells. And that can really change the metabolism, the physiology, of a cell and then by extension, of entire tissues and an entire organism. But the critical thing about this activity is that it was completely coupled to this small metabolic molecule in cells called NAD. No NAD, sirtuins are dead, okay? So NAD links sirtuins to diet and metabolism, because diet and metabolism affect the availability of NAD in cells.

So we came up with a hypothesis 10 years ago, when we discovered this activity, that sirtuins might really be the link between how diet affects how long you live and how diet affects your predisposition to diseases. And this was a, I think, radical idea. I think there are a lot of people out there still critical, don't believe it. But I think the data is mounting, in mice particularly, that says that this may actually be true. And so the idea would be that on a low-calorie diet, a diet that's been termed calorie restriction, we know that rodents live longer, and they resist diseases. They're disease-free under this diet. And we suggest that the reason for that, at least one of the reasons, one of the main reasons, is that this low-calorie diet activates sirtuins via this molecule NAD, and that the more active sirtuins then promote better survival and better ability to ward off diseases. So that's a very simple hypothesis that came from identifying this activity that I mentioned. That's one.

The second thing that came out of that is, once you have an understanding of what a protein does -- and you can actually measure that in a test tube now that just has that protein and, in this case, NAD -- it enables you to screen for drugs, for small molecules that can enhance that activity, and an open door for looking for small molecules that could up-regulate the activity of sirtuins. And that's led to sort of a flood of interest, I think probably the part of the story that's gotten the greatest notice in the press. So the first screens that were done identified a molecule found in red wine called resveratrol that's of a class of compounds that plants make in response to stress -- they're called polyphenols -- and these compounds could activate a sirtuin in a test tube, and they also could make cells live longer, yeast cells, and could make worms live longer. So the remarkable thing seemed to be that not only are sirtuins able to do this, but we might actually be able to influence their activity from outside with drugs.

And that really is, I think, where the excitement began and is still building, because I think that this is still not completely appreciated yet. So that was -- these are natural products, the resveratrol and the polyphenols, the things that are found in wine. But a company was started by David Sinclair and Kristoff Westfall called Sirtris about six years ago to try and look for new kinds of molecules now that are not natural products -- they're not found in nature -- by screening through libraries of different chemical compounds that have been synthesized. And there are new kinds of activators now of sirtuins, new chemicals, that can activate them much more potently than resveratrol. And it's going to be extremely exciting to test these molecules and see what they'll do.

So so far what we know is, both resveratrol and some of these new compounds have beneficial effects in mice. And what they do in mice -- they've been tested against various diseases. So what we would expect is, if these molecules are really activating sirtuins and can protect against diseases of aging, then we should be able to demonstrate that in a mouse. So it turns out if you feed a mouse basically a bad diet, the opposite of a calorie-restricted diet, so a diet high in fat, high in calories, the mice get diabetes, okay? Now it turns out these molecules, resveratrol and the newer compounds that activate the sirtuins, they can protect the mouse against diabetes. So the mouse will still eat a lot; the mouse will still even get fat, okay, but will stay metabolically healthy. So that's a pretty good demonstration that this idea is not so far out, but that there really is an opportunity here to use drugs to keep metabolism strong and intact in the face of caloric excess, okay?

But even more importantly for many of us like myself, who already -- I don't calorie restrict, but I don't eat to excess either, so I'm in good shape -- but even someone like myself would be able to get benefit from these molecules by activating sirtuins in addition to the benefit that I'm already getting by keeping myself in good shape. So I think it's a very promising area of research. And this company, this small company called Sirtris, was bought by one of the giants in the pharmaceutical industry, GSK, for something like three-quarters of a billion dollars a year ago. So obviously there's at least some validation in big pharma that these ideas are realistic and will be brought to fruition.

Question: What is the next frontier in understanding aging?

Leonard Guarente: Well, I think -- well, you know, my lab work's really on sirtuins, and I think there's so much to be done. So what we know now is just the tip of the iceberg about sirtuins. So first of all, there are seven of them in people, okay, and so far most of the studies have been focused on just one of those seven. Second of all, there are many tissues that have to be studied so we know what the sirtuins are doing in each and every tissue, so that we know what the effects of the drug are going to be, tissue by tissue. And that's going to take a long time, so we're deeply involved in that. The third thing is, will these sirtuins really protect against many diseases, or will they just protect against metabolic diseases like diabetes? So my lab is really focused now on nerve degenerative diseases, and we're testing the effect of activating the major human sirtuin, which is called SIRT1 -- it's also been called the survival gene -- and we're interested in what if we activate this in the brain? Will it protect the mouse against Alzheimer's disease, against Parkinson's disease, against Huntington's disease? And I think these are extremely important questions because they'll define the scope of what we're able to think about here and what we can start to attack pharmacologically.

Recorded on November 9, 2009

By studying how yeast ages, MIT's Leonard Guarente uncovered the gene that also controls how other organisms, and perhaps humans, grow old.

Videos
  • Beethovan and Picasso are the perfect examples for mastering the creative process.
  • Behind each of their works are countless studies and sketches.
  • The lesson? Never erase anything, keep iterating, and find new paths to familiar destinations.


New study finds the egg may actually 'choose' the Sperm

Here's the first evidence to challenge the "fastest sperm" narrative.

popular
Keep reading Show less
Big Think
Sponsored by Lumina Foundation

Upvote/downvote each of the videos below!

As you vote, keep in mind that we are looking for a winner with the most engaging social venture pitch - an idea you would want to invest in.

Lumina Foundation and Big Think have partnered to bring this entrepreneurial competition to life, and we hope you'll participate! We have narrowed down the competition to four finalists and will be announcing an audience's choice award and a judges' choice award in May.

The creator of the winning video — chosen by Big Think's audience, the Lumina Foundation, and an independent panel of experts (bios below) — will be flown to New York for a taping in the Big Think studio as a way to further promote their vision for a new, disruptive idea in post-secondary education.

Thank you to all of the contestants who spent time submitting applications, and best of luck to our final four competitors.

Finalist: Greater Commons - Todd McLeod

Greater Commons, founded by Todd McLeod and Andrew Cull, is an organization that helps people live happier, more successful and fulfilling lives through agile learning. The current education system is inefficient and exclusionary, in which many students who end up earning a degree, if at all, enter a career not related to their field of study. Greater Commons solves this problem and gap in post-high school secondary education in a variety of ways. Passionately and diligently, Great Commons helps others obtain skills, knowledge, wisdom, motivation, and inspiration so that they may live better lives.

Finalist: PeerFoward - Keith Frome

PeerForward is an organization dedicated to increasing the education and career success rates of students in low-income schools and communities by mobilizing the power of positive peer influence. PeerForward works with partner schools to select influential students as a part of a team, systemizing the "peer effect." Research in the fields of sociology of schools, social-emotional learning, adult-youth partnerships, and civic education demonstrates that students can have a positive effect on the academic outcomes of their peers. PeerForward is unique through its systemic solutions to post-secondary education.

Finalist: Cogniss - Leon Young

Cogniss combines technology and best practice knowledge to enable anyone to innovate and share solutions that advance lifelong learning. Cogniss is the only platform to integrate neuroscience, through which it solves the problem of access by providing a low-code platform that enables both developers and non-developers to build sophisticated education apps fast, and at a much lower cost. It addresses the uneven quality of edtech solutions by embedding research-based learning design into its software. App creators can choose from a rich set of artificial intelligence, game, social and data analytics, and gamification to build their perfect customized solution.

Finalist: Practera - Nikki James

Practera's mission is to create a world where everyone can learn through experience. Today's workplaces are increasingly dynamic and diverse, however, costly and time-consuming experiential learning is not always able to offer the right opportunities at scale. Many students graduate without developing the essential skills for their chosen career. Practera's team of educators and technologists see this problem as an opportunity to transform the educational experience landscape, through a CPL pedagogical framework and opportunities to apply students' strengths through active feedback.

Thank you to our judges!

Our expert judges are Lorna Davis, Dan Rosensweig, and Stuart Yasgur.

Lorna Davis is the Senior Advisor to Danone CEO and is a Global Ambassador for the B Corp movement. Lorna has now joined B-Lab, the non-for-profit that supports the B Corporation movement on an assignment to support the journey of large multi nationals on the path to using business as a force of good.

Dan Rosensweig joined Chegg in 2010 with a vision for transforming the popular textbook rental service into a leading provider of digital learning services for high school and college students. As Chairman and CEO of Chegg, Dan commits the company to fulfilling its mission of putting students first and helping them save time, save money and get smarter.

Stuart Yasgur leads Ashoka's Social Financial Services globally. At Ashoka, Stuart works with others to initiate efforts that have mobilized more than $500 million in funding for social entrepreneurs, engaged the G20 through the Toronto, Seoul and Los Cabos summits and helped form partnerships with leading financial institutions and corporations.

Again, thank you to our incredible expert judges.